GRCE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GRCE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Grace Therapeutics's book value per share for the quarter that ended in Sep. 2024 was $5.54.
During the past 12 months, Grace Therapeutics's average Book Value Per Share Growth Rate was -22.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -20.00% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 2.30% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -25.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Grace Therapeutics was 166.50% per year. The lowest was -61.60% per year. And the median was 2.50% per year.
Grace Therapeutics's current price is $3.58. Its book value per share for the quarter that ended in Sep. 2024 was $5.54. Hence, today's PB Ratio of Grace Therapeutics is 0.65.
During the past 13 years, the highest P/B Ratio of Grace Therapeutics was 6.25. The lowest was 0.12. And the median was 0.68.
The historical data trend for Grace Therapeutics's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grace Therapeutics Annual Data | |||||||||||||||||||||
Trend | Feb14 | Feb15 | Feb16 | Mar18 | Mar19 | Mar20 | Mar21 | Mar22 | Mar23 | Mar24 | |||||||||||
Book Value per Share | Get a 7-Day Free Trial | 6.91 | 12.82 | 14.67 | 9.14 | 6.57 |
Grace Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Book Value per Share | Get a 7-Day Free Trial | 7.10 | 6.88 | 6.57 | 5.85 | 5.54 |
For the Biotechnology subindustry, Grace Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Grace Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Grace Therapeutics's PB Ratio falls into.
Grace Therapeutics's Book Value Per Share for the fiscal year that ended in Mar. 2024 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (61.74 | - | 0.00) | / | 9.40 | |
= | 6.57 |
Grace Therapeutics's Book Value Per Share for the quarter that ended in Sep. 2024 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (56.13 | - | 0.00) | / | 10.14 | |
= | 5.54 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Grace Therapeutics (NAS:GRCE) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Thank you for viewing the detailed overview of Grace Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
George Kottayil | director | 49 OLD BEAR BROOK ROAD, PRINCETON NJ 08540 |
A Brian Davis | director | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
Edward Neugeboren | director | 282 NEW NORWALK ROAD, NEW CANAAN CT 06840 |
Vimal Kavuru | director | 11 MAACKA DRIVE, HOLMDEL NJ 07733 |
Donald Olds | director | 545 PROMENADE DU CENTROPOLIS, SUITE 100, LAVAL A8 H7T 0A3 |
Amresh Kumar | officer: VP Program Management | 3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5 |
Carrie D'andrea | officer: VP Clinical Operations | 3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5 |
Prashant Kohli | officer: Chief Executive Officer | 206 CAMBRIDGE LANE, NEWTOWN PA 13940 |
R. Loch Macdonald | officer: Chief Medical Officer | 200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922 |
Michael Derby | director | 303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591 |
William A Haseltine | director | |
Rajitha Grace 2018 Irrevocable Trust | 10 percent owner | 40 BEY LEA ROAD, SUITE C 202, TOMS RIVER NJ 08753 |
Swami Sambamurty Iyer | 10 percent owner | 20 TULSA COURT, MONMOUTH JUNCTION NJ 08852 |
Brian D. Ford | officer: CHIEF FINANCIAL OFFICER | 3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5 |
John Canan | director | C/O REV GROUP, INC., 111 EAST KILBOURN AVENUE, SUITE 2600, MILWAUKEE WI 53202 |
From GuruFocus
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By Marketwired • 09-05-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By Marketwired • 09-12-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus News • 11-15-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.